Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2012, with the announcement issued on April 2, 2012. The filing details a strategic investment transaction between GSK and Theravance, Inc., a biopharmaceutical company focused on respiratory disease, bacterial infections, and CNS/pain.
Key Financial Metrics and Transaction Details
The filing does not provide GSK's consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the period. The primary financial data relates to the specific investment transaction:
- Investment Amount: $212,887,000
- Shares Acquired: 10,000,000 shares of Theravance common stock
- Price Per Share: $21.2887 (representing a 7.5% premium to the 5-day volume-weighted average price)
- Post-Transaction Ownership: GSK will own approximately 26.8% of Theravance's total outstanding capital stock (increasing from approximately 18.3%).
Material Changes and Strategic Context
The material change reported is the increase in GSK's equity stake in Theravance. This transaction strengthens a long-standing collaboration initiated in 2002 and 2004 regarding respiratory therapies. Key programs under this alliance include:
- Relovair (FF/VI): An inhaled corticosteroid/LABA combination for COPD and asthma. Phase III development is complete, with regulatory applications planned for mid-2012 in the US and Europe.
- LAMA/LABA Programme: Currently in Phase III development for COPD.
- MABA Programme: A Bifunctional Muscarinic Antagonist-Beta 2 Agonist currently in Phase II development for COPD.
Despite the increased ownership, GSK expects to continue accounting for its total stake as an investment held at fair value due to existing governance agreements limiting voting rights.
Guidance, Risks, and Contingencies
Transaction Conditions: The deal is subject to closing conditions, including approval by Theravance stockholders at their Annual Meeting on May 15, 2012, and the expiration of the Hart-Scott-Rodino Act waiting period. Completion is expected shortly after the meeting.
Risks and Uncertainties: Both GSK and Theravance include standard forward-looking statement disclaimers. Specific risks cited include:
- Delays or difficulties in clinical studies and regulatory approvals.
- Potential failure of product candidates to prove safe or effective.
- Inability to obtain stockholder approval for the stock purchase.
- Market declines (S&P 500) that could trigger termination rights.
- Reliance on third-party manufacturers and collaborators.
Key Facts for Investor Verification
- Verify the outcome of the Theravance stockholder vote scheduled for May 15, 2012, which is a condition precedent to the transaction.
- Monitor the regulatory submission timeline for Relovair in the US and Europe, targeted for mid-2012.
- Confirm the accounting treatment of the investment remains at fair value despite the increased ownership percentage.
- Review the upcoming Theravance proxy statement for detailed information on the transaction and participant interests.